Therapy‑associated myelodysplastic syndrome with monosomy 7 arising in a Muir‑Torre Syndrome patient carrying SETBP1 mutation

Ullman,David; Baumgartner,Erin; Wnukowski,Nicholas; Koenig,Gabe; Mikhail,Fady M.; Pavlidakey,Peter; Peker,Deniz

doi:10.3892/mco.2017.1532

Therapy‑associated myelodysplastic syndrome with monosomy 7 arising in a Muir‑Torre Syndrome patient carrying SETBP1 mutation

Authors:
- David Ullman
- Erin Baumgartner
- Nicholas Wnukowski
- Gabe Koenig
- Fady M. Mikhail
- Peter Pavlidakey
- Deniz Peker
View Affiliations

Affiliations: Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Published online on: December 8, 2017 https://doi.org/10.3892/mco.2017.1532
Pages: 306-309

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Muir-Torre Syndrome (MTS) is a rare hereditary autosomal dominant cancer syndrome and is linked to hereditary non‑polyposis colorectal carcinoma (Lynch Syndrome). Individuals develop various skin neoplasms in addition to colorectal, endometrial and upper gastrointestinal malignancies. Therapy‑associated myelodysplastic syndrome (T‑MDS) is an aggressive hematologic malignancy and is considered a pre‑leukemic phase. T‑MDS is associated with prior exposure to chemo‑ and radiotherapy that potentially results in DNA damage. The current case report presents a 74-year-old male MTS patient with prior history of solid tumors and radiation therapy with new onset cytopenia. A subsequent bone marrow biopsy revealed multilineage dysplasia with a high blast count and a diagnosis of high grade T‑MDS was rendered. FISH and G‑banded karyotype analyses revealed 5q deletion and monosomy 7. This is a unique case of T‑MDS arising in the setting of MTS. Secondary malignancies including MDS and acute leukemia may occur in cancer survivors and are often associated with an unfavorable prognosis. This case demonstrates the need to be aware of the risk of secondary hematologic malignancies in cancer patients and a thorough clinical and lab work‑up are warranted in patients with persistent or transfusion requiring cytopenia(s).

View Figures

View References

1	Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
2	Wells K and Wise PE: Hereditary colorectal cancer syndromes. Surg Clin North Am. 97:605–625. 2017. View Article : Google Scholar : PubMed/NCBI
3	Lynch HT, Kimberling W, Albano WA, Lynch JF, Biscone K, Schuelke GS, Sandberg AA, Lipkin M, Deschner EE, Mikol YB, et al: Hereditary nonpolyposis colorectal cancer (lynch syndrome I and II). I. Clinical description of resource. Cancer. 56:934–938. 1985. View Article : Google Scholar : PubMed/NCBI
4	Bandipalliam P: Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer. 4:323–333. 2005. View Article : Google Scholar : PubMed/NCBI
5	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
6	Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, et al: Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 122:304–311. 2016. View Article : Google Scholar : PubMed/NCBI
7	Larson RA: Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 1–459. 2007.PubMed/NCBI
8	Pedersen-Bjergaard J, Andersen MT and Andersen MK: Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 1–397. 2007.PubMed/NCBI
9	Haase D: Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 87:515–526. 2008. View Article : Google Scholar : PubMed/NCBI
10	Godley LA and Larson RA: Therapy-related myeloid leukemia. Semin Oncol. 35:418–429. 2008. View Article : Google Scholar : PubMed/NCBI
11	Park HJ, Choi JH, Lee KA, Kim HC, Nam YS, Oh YH and Lee WS: A case of therapy-related acute myeloid leukemia following 5-fluorouracil chemotherapy. Korean J Intern Med. 27:115–117. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hangaishi A, Ogawa S, Mitani K, Hosoya N, Chiba S, Yazaki Y and Hirai H: Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. Blood. 89:1740–1747. 1997.PubMed/NCBI
13	Maeck L, Haase D, Schoch C, Hiddemann W and Alves F: Genetic instability in myelodysplastic syndrome: Detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations. Br J Haematol. 109:842–846. 2000. View Article : Google Scholar : PubMed/NCBI
14	Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ, Lin CC, Chen CY, Liu CY, Tseng MH, et al: Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 89:181–186. 2014. View Article : Google Scholar : PubMed/NCBI
15	Fabiani E, Falconi G, Fianchi L, Criscuolo M, Leone G and Voso MT: SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. Haematologica. 99:e152–e153. 2014. View Article : Google Scholar : PubMed/NCBI
16	Evans DG, Bowers N, Burkitt-Wright E, Miles E, Garg S, Scott-Kitching V, Penman-Splitt M, Dobbie A, Howard E, Ealing J, et al: Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. EBioMedicine. 7:212–220. 2016. View Article : Google Scholar : PubMed/NCBI
17	Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood. 110:4385–4395. 2007. View Article : Google Scholar : PubMed/NCBI
18	Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roddam PL, Roman E, Cartwright RA and Morgan GJ: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA. 98:pp. 11592–11597. 2001; View Article : Google Scholar : PubMed/NCBI
19	Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM and Smith MT: Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 94:803–807. 1999.PubMed/NCBI